| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNCI/80.1.21 |
| P698 | PubMed publication ID | 3276900 |
| P2093 | author name string | B Fisher | |
| J Jones | |||
| D L Wickerham | |||
| E R Fisher | |||
| N Wolmark | |||
| H Rockette | |||
| M Deutsch | |||
| R Caplan | |||
| C Redmond | |||
| H Lerner | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 21-29 | |
| P577 | publication date | 1988-03-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01 | |
| P478 | volume | 80 |
| Q73251663 | "Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival |
| Q67486083 | 3-D comparative study of proton vs. x-ray radiation therapy for rectal cancer |
| Q42870388 | A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer |
| Q35993810 | A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas |
| Q30931923 | A note from history: Landmarks in history of cancer, part 7. |
| Q34803980 | A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer |
| Q71784031 | A pilot study of a new therapeutic approach in the treatment of locally advanced stages of rectal cancer: Neoadjuvant radiation, chemotherapy and regional hyperthermia |
| Q90471895 | A review of preoperative chemoradiotherapy for lower rectal cancer |
| Q36371152 | ACR appropriateness criteria® resectable rectal cancer |
| Q73120378 | Abdominoperineal resection combined with pre- and postoperative radiation therapy in the treatment of low-lying rectal carcinoma |
| Q81381752 | Access to care and satisfaction in colorectal cancer patients |
| Q40852978 | Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. |
| Q28364849 | Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III |
| Q33839163 | Adjuvant and neoadjuvant chemoradiation therapy for primary colorectal cancer |
| Q34627277 | Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer |
| Q36101826 | Adjuvant and neoadjuvant treatment of resectable, locally advanced, rectal carcinoma with radiation therapy and chemotherapy |
| Q37153288 | Adjuvant chemoradiation for localized rectal cancer: current trends and future directions |
| Q34255956 | Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α |
| Q33698724 | Adjuvant chemotherapy |
| Q26775099 | Adjuvant chemotherapy for rectal cancer: Is it needed? |
| Q40904943 | Adjuvant medical therapy for colorectal cancer |
| Q72035296 | Adjuvant post-operative radiotherapy vs radiotherapy plus 5-FU and levamisole in patients with TNM stage II–III resectable rectal cancer. A phase III randomized clinical trial |
| Q41416682 | Adjuvant radiation therapy for adenocarcinoma of the rectum |
| Q77087330 | Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials |
| Q36260173 | Adjuvant radiotherapy improves cause specific survival in stage II, not stage III mucinous carcinoma of the rectum |
| Q35758360 | Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer |
| Q36130803 | Adjuvant therapy for adenocarcinoma of the rectum |
| Q61649344 | Adjuvant therapy for colorectal cancer |
| Q36752059 | Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study? |
| Q68056412 | Adjuvant therapy for colorectal carcinoma |
| Q37462241 | Adjuvant therapy for rectal cancer |
| Q35767246 | Adjuvant therapy for rectal cancer in the elderly |
| Q34176699 | Adjuvant therapy for resectable rectal adenocarcinoma |
| Q73728285 | Adjuvant therapy of colorectal cancer |
| Q40476755 | Adjuvant treatment for colorectal cancer: ‘State of the Art’—messages from recent trials |
| Q40481695 | Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database |
| Q40895672 | Adjuvant treatment in the curative management of rectal cancer: a critical review of the results of clinical randomised trials |
| Q73574215 | Adjuvant treatment of colorectal cancer |
| Q53313028 | Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). |
| Q34181264 | Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. |
| Q43853122 | Adoption of Preoperative Radiation Therapy for Rectal Cancer From 2000 to 2006: A Surveillance, Epidemiology, and End Results Patterns-of-Care Study |
| Q36025983 | Advances and challenges in treatment of locally advanced rectal cancer |
| Q67586741 | Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma |
| Q73149382 | Aggressive versus conventional strategies in the treatment of rectal adenocarcinoma |
| Q35182207 | An evidence-based estimate of the appropriate radiotherapy utilization rate for colorectal cancer |
| Q31106341 | An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. |
| Q36905075 | An individualized conditional survival calculator for patients with rectal cancer |
| Q40414780 | Analysis of local recurrence rates after surgery alone for rectal cancer. |
| Q42225415 | Approach to rectal cancer surgery |
| Q88517042 | Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection |
| Q44779545 | Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma |
| Q38736426 | CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α. |
| Q36792342 | Can only chemoradiotherapy and chemotherapy treatment be applied to patients with rectal cancer who could not be operated? |
| Q31138958 | Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base |
| Q80510550 | Cancers of the large bowel and hepatobiliary tract |
| Q81086290 | Cancers of the large bowel and hepatobiliary tract |
| Q61584264 | Changes in the practice of adjuvant radiotherapy in resectable rectal cancer within a French well-defined population |
| Q90412884 | Chemo-Radiation After Upfront Rectal Resections-a Clinical Dilemma |
| Q77214599 | Chemoradiation for rectal cancer: current methods |
| Q37353934 | Chemoradiotherapy and adjuvant chemotherapy for rectal cancer |
| Q34388693 | Chemoradiotherapy for rectal cancer--is there an optimal combination? |
| Q34989842 | Chemoradiotherapy in the treatment of rectal cancer |
| Q35572017 | Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer |
| Q78478993 | Chemotherapy for colorectal cancer |
| Q40484654 | Chemotherapy in Colorectal Carcinoma |
| Q73236924 | Chemotherapy of Colorectal Cancer |
| Q48262835 | Clinically Node Negative, Pathologically Node Positive Rectal Cancer Patients Who Did Not Receive Neoadjuvant Therapy. |
| Q93917269 | Colorectal cancer |
| Q61868261 | Colorectal cancer |
| Q43622616 | Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum |
| Q37231196 | Comparison between preoperative and postoperative concurrent chemoradiotherapy for rectal cancer: an institutional analysis |
| Q84973025 | Comparison of treatment results between surgery alone, preoperative short-course radiotherapy, or long-course concurrent chemoradiotherapy in locally advanced rectal cancer |
| Q24241723 | Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer |
| Q24244861 | Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer |
| Q44859951 | Conservative management of extensive low-lying rectal carcinomas with transanal local excision and combined preoperative and postoperative radiation therapy. A report of a phase I-II trial |
| Q34259449 | Conservative treatment of rectal adenocarcinoma |
| Q40423881 | Conservative treatment of rectal cancer with local excision and postoperative radiation therapy |
| Q36421968 | Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer |
| Q35572003 | Controversies in the surgical management of rectal cancer |
| Q36944056 | Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer |
| Q34615945 | Developments and quality assurance in rectal cancer surgery |
| Q35982503 | Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft |
| Q36097082 | Do all locally advanced rectal cancers require radiation? A review of literature in the modern era. |
| Q68210986 | Does Preoperative Radiation Therapy Enhance the Probability of Local Control and Survival in High-risk Distal Rectal Cancer? |
| Q44148654 | Effect of total mesorectal excision on the outcome of rectal cancer after standardized postoperative radiochemotherapy: do randomized studies translate into clinical routine? |
| Q83821349 | Effects of postoperative adjuvant radiotherapy on recurrence and survival in stage III rectal cancer |
| Q44108177 | Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial |
| Q33746878 | Efficacy of postoperative concurrent chemoradiation for resectable rectal cancer: a single institute experience |
| Q30484649 | Endorectal ultrasound: its role in the diagnosis and treatment of rectal cancer |
| Q36213998 | Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy |
| Q35435861 | Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice |
| Q72854638 | Evaluation of preoperative radiation therapy in operable colorectal cancer |
| Q39390635 | Evolving role of neoadjuvant therapy in rectal cancer |
| Q43765100 | Fatigue during preoperative chemoradiation for resectable rectal cancer |
| Q37416816 | Feasibility of adequate resectable rectal cancer treatment in a third-level hospital |
| Q47628540 | Fertility maintenance and 5-fluorouracil timing within the mammalian fertility cycle |
| Q54444904 | Five fractions of preoperative radiotherapy for selected cases of rectal carcinoma: long-term tumor control and tolerance to treatment. |
| Q33637997 | Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer |
| Q36751259 | Flow cytometric analysis of DNA content in colorectal carcinoma |
| Q41138044 | Gender differences in pharmacokinetics |
| Q35771996 | How safe is adjuvant chemotherapy and radiotherapy for rectal cancer? |
| Q89502186 | Impact of Adjuvant Therapy Type on Survival in Stage II/III Rectal Cancer Without Preoperative Chemoradiation: A Korean Multicenter Retrospective Study |
| Q40632454 | Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. |
| Q47140514 | Impact of neoadjuvant and adjuvant radiotherapy on disease-specific survival in patients with stages II-IV rectal cancer |
| Q33791360 | Impact of the new AJCC staging system and adjuvant treatment in rectal cancer |
| Q33593850 | Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial |
| Q99617097 | Improving Rectal Cancer Outcomes with the National Accreditation Program for Rectal Cancer |
| Q33509625 | Inclusion of women in clinical trials |
| Q77214611 | Induction therapy for rectal carcinoma |
| Q36306673 | Interval between Surgery and Radiation Therapy Is an Important Prognostic Factor in Treatment of Rectal Cancer. |
| Q34391337 | Is laparoscopic colorectal cancer surgery equal to open surgery? An evidence based perspective |
| Q77128739 | Is radiochemotherapy necessary in the treatment of rectal cancer? |
| Q33534201 | Is there a standard adjuvant treatment for rectal cancer? |
| Q60629765 | La prise en charge du cancer colorectal en France : vers une amélioration des pratiques et des résultats ? |
| Q36116454 | Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy |
| Q33431971 | Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer |
| Q35614048 | Laparoscopic total mesorectal excision (TME) for rectal cancer surgery: long-term outcomes |
| Q90344727 | Local Irradiation Modulates the Pharmacokinetics of Metabolites in 5-Fluorouracil-Radiotherapy-Pharmacokinetics Phenomenon |
| Q41000719 | Local and regional recurrence of carcinoma of the colon and rectum: I. Tumour-host factors and adjuvant therapy. |
| Q35579044 | Local pelvic irradiation modulates Pharmacokinetics of 5-Fluorouracil in the plasma but not in the Lymphatic System. |
| Q37895253 | Locally advanced rectal cancer: a comparison of management strategies |
| Q58005112 | Locally advanced rectal carcinoma: Pelvic control and morbidity following preoperative radiation therapy, resection, and intraoperative radiation therapy |
| Q74451545 | Locoregional recurrence and survival after curative resection of adenocarcinoma of the colon |
| Q43436444 | Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer |
| Q45204907 | Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. |
| Q92716670 | Making sense of adjuvant chemotherapy in colorectal cancer |
| Q77165835 | Management of colorectal cancer |
| Q34321692 | Management of locally advanced rectal cancer |
| Q36097091 | Management of stage II/III rectal cancer |
| Q28478505 | Matrix metalloproteinase-8 mediates the unfavorable systemic impact of local irradiation on pharmacokinetics of anti-cancer drug 5-Fluorouracil |
| Q33349114 | Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer |
| Q33839180 | Multidisciplinary management of recurrent colorectal cancer |
| Q49564059 | Neoadjuvant Strategies: Locally Advanced Rectal Cancer |
| Q39172475 | Neoadjuvant Treatment for Locally Advanced Rectal Cancer: New Concepts in Clinical Trial Design |
| Q41692918 | Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. |
| Q89905982 | Neoadjuvant radiotherapy improves overall survival for T3/4N+M0 rectal cancer patients: a population-based study of 20300 patients |
| Q33961175 | Neoadjuvant therapy in the treatment of high risk rectal carcinoma. |
| Q37158143 | Neoadjuvant treatment of rectal cancer: where are we now? |
| Q36058487 | Neoadjuvant treatment response as an early response indicator for patients with rectal cancer |
| Q36871507 | Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer |
| Q35951764 | Oncologic Outcomes and Risk Factors for Recurrence after Tumor-specific Mesorectal Excision of Rectal Cancer: 782 Cases |
| Q45071422 | Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. |
| Q64274403 | Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer |
| Q41633576 | Outcomes in patients treated by laparoscopic resection of rectal carcinoma after neoadjuvant therapy for rectal cancer. |
| Q73202301 | Outcomes of patients receiving radiation for carcinoma of the rectum. Results of the 1988-1989 patterns of care study |
| Q35089172 | Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer |
| Q73551696 | Palliative reirradiation for recurrent rectal cancer |
| Q81167506 | Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation |
| Q38079162 | Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy |
| Q36824126 | Patterns of Colorectal Cancer Care in the United States: 1990-2010. |
| Q71773008 | Patterns of recurrence following pelvic exenteration and external radiotherapy for locally advanced primary rectal adenocarcinoma |
| Q72452708 | Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma |
| Q33742806 | Pelvic exenteration for carcinoma of the colon and rectum |
| Q34851427 | Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy |
| Q72871387 | Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: a phase II study |
| Q34210436 | Perioperative radiotherapy and concurrent radiochemotherapy in rectal cancer |
| Q43842513 | Personalized treatment of colorectal cancer in old age |
| Q36621562 | Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer |
| Q73850882 | Phase II trial of adjuvant radiation and intraperitoneal 5-fluorouracil for locally advanced colon cancer: results with 10-year follow-up |
| Q36937011 | Post operative stereotactic radiosurgery for positive or close margins after preoperative chemoradiation and surgery for rectal cancer |
| Q35542484 | Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer |
| Q34634601 | Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials |
| Q24201072 | Postoperative adjuvant chemotherapy in rectal cancer operated for cure |
| Q37447997 | Postoperative complications in patients with rectal cancer are associated with delays in chemotherapy that lead to worse disease-free and overall survival |
| Q74574108 | Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group |
| Q78111187 | Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperativ |
| Q37153308 | Potential benefits of integration of therapies with chemoradiation in rectal cancer. |
| Q74574102 | Pre- or postoperative radiotherapy in rectal cancer--more to learn? |
| Q35588277 | Pre-operative and post-operative radiotherapy and rectal cancer |
| Q73155040 | Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer |
| Q36450762 | Preoperative and adjuvant treatment of localized rectal cancer |
| Q81294629 | Preoperative chemoradiation therapy shows improved clinical benefit in patients with rectal cancer |
| Q73307138 | Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation |
| Q73045474 | Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study |
| Q32149044 | Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma |
| Q44520757 | Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study. |
| Q57035666 | Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma |
| Q71697476 | Preoperative radiotherapy for rectal cancer: benefits and controversies |
| Q37158196 | Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. |
| Q54943410 | Preoperative short-course radiotherapy in rectal cancer patients: results and prognostic factors. |
| Q71170169 | Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy |
| Q41416890 | Preservation of the anus in the therapy of distal rectal cancers |
| Q77737288 | Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer |
| Q78094289 | Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer |
| Q34110610 | Prognostic nomograms for predicting survival and distant metastases in locally advanced rectal cancers |
| Q43636065 | Racial and ethnic disparities in outcomes with radiation therapy for rectal adenocarcinoma |
| Q71868292 | Radiation dose-response of human tumors |
| Q40872288 | Radiation therapy for colorectal cancer. |
| Q92716703 | Radiation therapy for rectal cancer |
| Q69485858 | Radiation therapy in the management of rectal cancer |
| Q33841154 | Radiation therapy of the older patient |
| Q61481461 | Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial |
| Q41382927 | Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment |
| Q41313373 | Radiotherapy in the aged. |
| Q73093115 | Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer |
| Q34322325 | Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group |
| Q85173923 | Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: 10-Year Follow-Up |
| Q34584732 | Randomized clinical trials in colon cancer |
| Q34584739 | Randomized clinical trials in rectal and anal cancer |
| Q71697481 | Randomized study on preoperative radiotherapy in rectal carcinoma. Stockholm Colorectal Cancer Study Group |
| Q77425371 | Recent advances in the treatment and outcome of locally advanced rectal cancer |
| Q33787455 | Recent advances in the treatment of rectal carcinoma |
| Q37962660 | Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain. |
| Q63517619 | Rectal and Colon Cancer: Background and Clinical Evidence |
| Q84180590 | Rectal cancer |
| Q57172366 | Rectal cancer MRI: protocols, signs and future perspectives radiologists should consider in everyday clinical practice |
| Q77936425 | Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy |
| Q97544246 | Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy |
| Q37034524 | Rectal cancer staging: focus on the prognostic significance of the findings described by high-resolution magnetic resonance imaging |
| Q81041981 | Rectal cancer: Current issues |
| Q35572006 | Rectal cancer: Preoperative versus postoperative irradiation as a component of adjuvant treatment. |
| Q42555130 | Rectal cancer: a review |
| Q40963344 | Rectal cancer: a review of randomized trials of adjuvant radiotherapy |
| Q33631020 | Reflections on randomised controlled trials in surgery |
| Q57566978 | Regional variations in management of rectal cancer in France |
| Q46303039 | Relation of surgeon and hospital volume to processes and outcomes of colorectal cancer surgery |
| Q35588274 | Results of radical surgery for rectal cancer |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q33516922 | Revised TN categorization for colon cancer based on national survival outcomes data |
| Q33627785 | Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes |
| Q41594853 | Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. |
| Q40472501 | Role of adjuvant therapy in surgically resected colorectal carcinoma |
| Q52871348 | Role of circumferential margin involvement in the local recurrence of rectal cancer. |
| Q34509131 | Role of radiation therapy in the treatment of resectable rectal adenocarcinoma |
| Q92713073 | Short-course or long-course radiation therapy as a part of a neoadjuvant regimen for stage II & III rectal adenocarcinoma? |
| Q50950540 | Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. |
| Q70804020 | Sphincter-saving surgery with and without pre-operative radiation therapy as treatment for adenocarcinoma of the mid-rectum |
| Q50889498 | Stage I rectal cancer: identification of high-risk patients. |
| Q60692463 | Stage-Specific Survival Differences Associated with Postoperative Radiotherapy for Gastrointestinal Cancers |
| Q42388377 | Statistical aspects of prognostic factor studies in oncology |
| Q34958703 | Strategies in the management of mid and distal rectal cancer with total mesorectal excision |
| Q37072492 | Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. |
| Q61649343 | Surgical Treatment of Adenocarcinoma of the Rectum |
| Q36762886 | Surgical excision alone is adequate treatment for primary colorectal cancer |
| Q79249835 | Surgical quality assurance in breast, gastric and rectal cancer |
| Q34989823 | Surgical treatment of rectal cancer |
| Q55082844 | Survival Contradiction Between Stage IIA and Stage IIIA Rectal Cancer: A Retrospective Study. |
| Q35011194 | Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population |
| Q44447446 | Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum. |
| Q28084403 | Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease |
| Q35572015 | Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents |
| Q73164021 | T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy |
| Q34339987 | The Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colorectal Cancer is Independent of Age and Comorbidity |
| Q36119749 | The Globalization of Cooperative Groups |
| Q88336504 | The Selective Use of Radiation Therapy in Rectal Cancer Patients |
| Q74180894 | The changing role of radiation therapy in the management of rectal cancer |
| Q40423873 | The current role of radiotherapy in colorectal cancer |
| Q40486003 | The effect of H2 antagonists on proliferation and apoptosis in human colorectal cancer cell lines |
| Q34234935 | The emerging role of neoadjuvant chemotherapy for rectal cancer |
| Q36973199 | The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project |
| Q38223654 | The impact of pathologic nodal status on survival following neoadjuvant chemoradiation for locally advanced rectal cancer |
| Q83352619 | The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002 |
| Q73037089 | The influence of pre-operative radiation therapy on the patterns of recurrence in rectal adenocarcinoma |
| Q74552926 | The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy |
| Q40886139 | The role of adjuvant chemotherapy in the treatment of colorectal cancer |
| Q41563195 | The role of adjuvant radiation therapy in the treatment of colorectal cancer |
| Q67697854 | The role of endocavitary irradiation for limited lesions of the rectum |
| Q36537071 | The role of postoperative pelvic radiation in stage IV rectal cancer after resection of primary tumor |
| Q78014380 | The role of radiotherapy in rectal cancer |
| Q34558185 | The role of radiotherapy in rectal cancer |
| Q77422077 | The role of radiotherapy in the surgical management of gastrointestinal cancer |
| Q33760645 | The role of surgery and chemoradiation therapy for cancer of the rectum |
| Q37766529 | The role of targeted agents in preoperative chemoradiation for rectal cancer |
| Q35036365 | The role of total mesorectal excision in the management of rectal cancer. |
| Q37694845 | The survival and clinicopathological differences between patients with stage IIIA and stage II rectal cancer: An analysis of 12,036 patients in the SEER database |
| Q40423884 | The value of adjuvant radio(chemo)therapy for rectal cancer |
| Q55241689 | Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study. |
| Q92189101 | Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy |
| Q33932019 | Treatment of colon and rectal cancer |
| Q40900115 | Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy |
| Q36351882 | Treatment of locally advanced rectal cancer: controversies and questions |
| Q38170032 | Treatment of stage II-III rectal cancer patients |
| Q37340518 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer |
| Q36977683 | UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction |
| Q73621393 | Where next in the treatment of rectal cancer? |
| Q39474680 | Zelen randomization: attitudes of parents participating in a neonatal clinical trial |
| Q73611581 | [Adjuvant radio-chemotherapy of cancers of the rectum] |
| Q77773813 | [Curative treatment of rectal cancer] |
| Q79268937 | [Indications for neoadjuvant therapy in rectal carcinoma] |
| Q80700849 | [Problems in the treatment of upper rectal carcinoma] |
Search more.